DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Dapagliflozin; saxagliptin hydrochlorideis the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Dapagliflozin; saxagliptin hydrochloride has three hundred and forty-nine patent family members in forty-seven countries.
There are twenty-six drug master file entries for dapagliflozin; saxagliptin hydrochloride. One supplier is listed for this compound.
Recent Clinical Trials for dapagliflozin; saxagliptin hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
|Sabyasachi Sen||Phase 4|
|Third Affiliated Hospital, Sun Yat-Sen University||Phase 4|
|Peking University Shenzhen Hospital||Phase 4|
Pharmacology for dapagliflozin; saxagliptin hydrochloride
|Drug Class||Sodium-Glucose Cotransporter 2 Inhibitor |
Dipeptidyl Peptidase 4 Inhibitor
|Mechanism of Action||Sodium-Glucose Transporter 2 Inhibitors |
Dipeptidyl Peptidase 4 Inhibitors
|Country||Patent Number||Estimated Expiration|
|South Africa||200206816||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|1261586||CA 2012 00014||Denmark||Start Trial|
|1506211||PA2013008||Lithuania||Start Trial||PRODUCT NAME: DAPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/12/795/001 - EU/1/12/795/010 20121112|
|1506211||C20130006 00074||Estonia||Start Trial||PRODUCT NAME: DAPAGLIFLOZIN;REG NO/DATE: K(2012)8378 12.11.2012|
|1506211||179 5017-2014||Slovakia||Start Trial||PRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116|
|1261586||10C0010||France||Start Trial||PRODUCT NAME: SAXAGLIPTINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, Y COMPRIS LE CHLORHYDRATE DE SAXAGLIPTINE; NAT. REGISTRATION NO/DATE: EU/1/09/545/001 20091001; FIRST REGISTRATION: EU/1/09/454/001 20091001|
|1506211||132014902277722||Italy||Start Trial||PRODUCT NAME: UNA COMBINAZIONE DI DAPAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE E METFORMINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE COME PROTETTI DAL BREVETTO DI BASE EP1506211(XIGDUO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/900, 20140116|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.